CSL VIFOR AND TRAVERE THERAPEUTICS ANNOUNCE SWISSMEDIC APPROVAL OF FILSPARI® (SPARSENTAN) FOR THE TREATMENT OF IGA NEPHROPATHY

Reuters · 10/17 06:30

Please log in to view news